Skip to main content
NCBI home page
Gut logoLink to Gut
. 1992 Apr;33(4):513–517. doi: 10.1136/gut.33.4.513

Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C.

A B Hawthorne 1, N K Boughton-Smith 1, B J Whittle 1, C J Hawkey 1
PMCID: PMC1374069  PMID: 1316305

Abstract

The in vitro synthesis of leukotriene B4 (LTB4) was evaluated in colorectal biopsy specimens and resection tissue from patients with inflammatory bowel disease. The in vitro formation of LTB4 from biopsy tissues stimulated with calcium ionophore A23187 correlated with the degree of mucosal inflammation assessed at sigmoidoscopy, and with neutrophil infiltration measured as myeloperoxidase activity. Biopsy specimens from patients taking prednisolone formed less LTB4 than those from patients not on prednisolone, with comparable levels of inflammation seen at sigmoidoscopy. The formation of LTB4 was reduced dose-dependently by the acetohydroxamic acid 5-lipoxygenase inhibitor BWA4C, with no significant inhibition of prostaglandin E2 or thromboxane B2 synthesis. In inflamed colonic resection tissue from colitic patients, the IC50 for inhibition of LTB4 formation by BWA4C was 0.03 mumol/l, compared with an IC50 of 0.8 mumol/l for NDGA. Thus, BWA4C is a potent and selective inhibitor of LTB4 synthesis in colonic tissue from patients with ulcerative colitis. Acetohydroxamic acid 5-lipoxygenase inhibitors, exemplified by BWA4C, may be useful to evaluate the clinical importance of LTB4 in ulcerative colitis, and offer a novel therapy for the disease.

Full text

PDF
513

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aehringhaus U., Wölbling R. H., König W., Patrono C., Peskar B. M., Peskar B. A. Release of leukotriene C4 from human polymorphonuclear leucocytes as determined by radioimmunoassay. FEBS Lett. 1982 Sep 6;146(1):111–114. doi: 10.1016/0014-5793(82)80715-1. [DOI] [PubMed] [Google Scholar]
  2. BARON J. H., CONNELL A. M., LENNARD-JONES J. E. VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS. Br Med J. 1964 Jan 11;1(5375):89–92. doi: 10.1136/bmj.1.5375.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boughton-Smith N. K., Hawkey C. J., Whittle B. J. Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa. Gut. 1983 Dec;24(12):1176–1182. doi: 10.1136/gut.24.12.1176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boughton-Smith N. K., Wallace J. L., Morris G. P., Whittle B. J. The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br J Pharmacol. 1988 May;94(1):65–72. doi: 10.1111/j.1476-5381.1988.tb11500.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boughton-Smith N. K., Wallace J. L., Whittle B. J. Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions. 1988 Aug;25(1-2):115–123. doi: 10.1007/BF01969102. [DOI] [PubMed] [Google Scholar]
  6. Boughton-Smith N. K., Whittle B. J. Failure of the inhibition of rat gastric mucosal 5-lipoxygenase by novel acetohydroxamic acids to prevent ethanol-induced damage. Br J Pharmacol. 1988 Sep;95(1):155–162. doi: 10.1111/j.1476-5381.1988.tb16559.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hawkey C. J., Boughton-Smith N. K., Whittle B. J. Modulation of human colonic arachidonic acid metabolism by sulfasalazine. Dig Dis Sci. 1985 Dec;30(12):1161–1165. doi: 10.1007/BF01314051. [DOI] [PubMed] [Google Scholar]
  8. Krawisz J. E., Sharon P., Stenson W. F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984 Dec;87(6):1344–1350. [PubMed] [Google Scholar]
  9. Lauritsen K., Laursen L. S., Bukhave K., Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology. 1986 Oct;91(4):837–844. doi: 10.1016/0016-5085(86)90684-0. [DOI] [PubMed] [Google Scholar]
  10. Lauritsen K., Laursen L. S., Bukhave K., Rask-Madsen J. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut. 1987 Sep;28(9):1095–1099. doi: 10.1136/gut.28.9.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lee T. H., Horton C. E., Kyan-Aung U., Haskard D., Crea A. E., Spur B. W. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Clin Sci (Lond) 1989 Aug;77(2):195–203. doi: 10.1042/cs0770195. [DOI] [PubMed] [Google Scholar]
  12. Lobos E. A., Sharon P., Stenson W. F. Chemotactic activity in inflammatory bowel disease. Role of leukotriene B4. Dig Dis Sci. 1987 Dec;32(12):1380–1388. doi: 10.1007/BF01296664. [DOI] [PubMed] [Google Scholar]
  13. Morris G. P., Beck P. L., Herridge M. S., Depew W. T., Szewczuk M. R., Wallace J. L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989 Mar;96(3):795–803. [PubMed] [Google Scholar]
  14. Payne A. N., Garland L. G., Lees I. W., Salmon J. A. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on bronchial anaphylaxis in anaesthetized guinea-pigs. Br J Pharmacol. 1988 Jun;94(2):540–546. doi: 10.1111/j.1476-5381.1988.tb11558.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Peskar B. M., Dreyling K. W., Peskar B. A., May B., Goebell H. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions. 1986 Jun;18(3-4):381–383. doi: 10.1007/BF01965001. [DOI] [PubMed] [Google Scholar]
  16. Peterson G. L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977 Dec;83(2):346–356. doi: 10.1016/0003-2697(77)90043-4. [DOI] [PubMed] [Google Scholar]
  17. Sharon P., Stenson W. F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984 Mar;86(3):453–460. [PubMed] [Google Scholar]
  18. Tateson J. E., Randall R. W., Reynolds C. H., Jackson W. P., Bhattacherjee P., Salmon J. A., Garland L. G. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo. Br J Pharmacol. 1988 Jun;94(2):528–539. doi: 10.1111/j.1476-5381.1988.tb11557.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vanderhoek J. Y., Bryant R. W., Bailey J. M. Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. J Biol Chem. 1980 Nov 10;255(21):10064–10066. [PubMed] [Google Scholar]
  20. Vilaseca J., Salas A., Guarner F., Rodriguez R., Malagelada J. R. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology. 1990 Feb;98(2):269–277. doi: 10.1016/0016-5085(90)90814-h. [DOI] [PubMed] [Google Scholar]
  21. Wallace J. L., Keenan C. M. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol. 1990 Apr;258(4 Pt 1):G527–G534. doi: 10.1152/ajpgi.1990.258.4.G527. [DOI] [PubMed] [Google Scholar]
  22. Wallace J. L., Keenan C. M. Leukotriene B4 potentiates colonic ulceration in the rat. Dig Dis Sci. 1990 May;35(5):622–629. doi: 10.1007/BF01540411. [DOI] [PubMed] [Google Scholar]
  23. Wallace J. L., MacNaughton W. K., Morris G. P., Beck P. L. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology. 1989 Jan;96(1):29–36. doi: 10.1016/0016-5085(89)90760-9. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES